Literature DB >> 9312123

A new function of p120-GTPase-activating protein. Prevention of the guanine nucleotide exchange factor-stimulated nucleotide exchange on the active form of Ha-ras p21.

C Giglione1, M C Parrini, S Baouz, A Bernardi, A Parmeggiani.   

Abstract

This work studies the coordination of the action of GTPase-activating protein (GAP) and guanine nucleotide exchange factor (GEF) on activated human c-Ha-Ras p21. Purified human p120-GAP was obtained with a new efficient procedure. To distinguish the GTPase-activating effect of p120-GAP from other effects dependent on the interaction with activated Ha-Ras, the nonhydrolyzable GTP analogue guanosine 5'-O-(thiotriphosphate) (GTPgammaS) was used. The results showed that the GTPgammaS/GTPgammaS exchange enhanced by the C-terminal catalytic domain of the yeast GEF Sdc25p (C-Sdc25p) is prevented by p120-GAP. This effect is strictly specific for the activated form of Ha-Ras, the target of GAP; no effect on Ha-Ras.GDP was detectable. The GAP catalytic domain also inhibited C-Sdc25p but to a lower extent. The interfering effect by p120-GAP was also evident in a homologous mammalian system, using full-length mouse RasGEF, its C-terminal half-molecule, or C-terminal catalytic domain. As a consequence of this inhibition, presence of p120-GAP enhanced the regeneration of Ha-Ras.GTPgammaS by GEF at a GDP:GTPgammaS ratio mimicking the in vivo GDP:GTP ratio. Our work describes a novel function of p120-GAP and suggests a mechanism by which GAP protects Ha-Ras.GTP in vivo against unproductive exchanges. This constrain is likely involved in the regulation of the physiological GDP/GTP cycle of Ras and in the action of p120-GAP as downstream effector of Ras. Helix alpha3 is proposed as a Ras element playing a key-role in the interference between GAP and GEF on Ras.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9312123     DOI: 10.1074/jbc.272.40.25128

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Molecular dynamics simulations of Gly-12-->Val mutant of p21(ras): dynamic inhibition mechanism.

Authors:  N Futatsugi; M Tsuda
Journal:  Biophys J       Date:  2001-12       Impact factor: 4.033

Review 2.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

Review 3.  Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2.

Authors:  Kunwar Singh; Sumanth Gollapudi; Sasha Mittal; Corinn Small; Jyoti Kumar; Robert S Ohgami
Journal:  Diagnostics (Basel)       Date:  2021-03-27

Review 4.  Emerging role of non-coding RNAs in the regulation of KRAS.

Authors:  Soudeh Ghafouri-Fard; Zeinab Shirvani-Farsani; Bashdar Mahmud Hussen; Mohammad Taheri; Reza Jalili Khoshnoud
Journal:  Cancer Cell Int       Date:  2022-02-09       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.